Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 35 recruiting now early-phase tilt

Peripheral Arterial Disease: early-phase trial registry

35 of 80 indexed Peripheral Arterial Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #173 of 28,707 conditions by registered trial count.

80 US clinical trials · 35 currently recruiting · #173 of 28,707 conditions by registered trial count

Peripheral Arterial Disease: 80 US clinical trials tracked, 35 recruiting.

Peripheral Arterial Disease is the subject of 80 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is University of Nebraska, running 7 of these trials.

Enrollment posture brief

Registry condition peripheral-arterial-disease

OPEN 35 | RECR 44% | LATE 7 | EARLY 14 | RANK #173 | SPON 7

Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)

Small-cell Lung Cancer47.5%Stage IV Lung Cancer AJCC v845.1%Peripheral Arterial Dise (th…44%Small Lymphocytic Lymphoma43.9%Liver Cancer37%
Open-enrollment share among volume-matched conditions near Peripheral Arterial Disease

Peripheral Arterial Disease lists 35 open slots (44% of 80 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Peripheral Arterial Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Peripheral Arterial Disease is recruiting above its size-band peers.

    35 of 80 indexed trials (43.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Peripheral Arterial Disease trials is spread across many organizations.

    University of Nebraska accounts for 7 of 80 trials (8.8%). 56 distinct sponsors appear on at least one study for this condition label.

  3. Typical Peripheral Arterial Disease enrolment sits around 100 participants.

    Median target enrolment is 100 among the 80 trials that report a genuine target (sentinel values excluded). 40 of those (50%) plan for fewer than 100 participants.

  4. Peripheral Arterial Disease research is mostly interventional.

    62 interventional and 18 observational studies make up this index (77.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 19Phase 25Phase 33Phase 44

Open and recent trials

80 total, page 1 of 2

RECRUITING 300,000 participants

A Real-World Registry of Chronic Wounds and Ulcers

U.S. Wound Registry

NCT02280733

RECRUITING 14,000 participants

Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

Baylor Research Institute

NCT01904851

RECRUITING Phase 3 6,150 participants

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

Population Health Research Institute

NCT04774159

RECRUITING Phase 3 1,205 participants

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Eli Lilly and Company

NCT07223593

RECRUITING 1,000 participants

Advanta VXT and Flixene PMCF Registry

Atrium Medical Corporation

NCT07161583

RECRUITING 500 participants

Pounce™ Thrombectomy System Retrospective Registry

SurModics

NCT05868161

RECRUITING 450 participants

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

Endologix

NCT06315023

RECRUITING NA 400 participants

Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease

Mayo Clinic

NCT06952543

RECRUITING NA 376 participants

SELUTION4BTK Trial

M.A. Med Alliance S.A.

NCT05055297

RECRUITING NA 350 participants

Intravascular Ultrasound Imaging Guidance for Optimal Revascularization of Limb Arteries

Baylor Research Institute

NCT07353905

RECRUITING Phase 4 350 participants

Vascular Trial Associated Registry Pilot

Corewell Health West

NCT07076082

RECRUITING NA 300 participants

Prehabilitation and Rehabilitation in PAD

Palo Alto Veterans Institute for Research

NCT06566976

RECRUITING NA 244 participants

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

W.L.Gore & Associates

NCT05811364

RECRUITING Phase 3 210 participants

SMART Exercise for PAD

Northwestern University

NCT06032065

RECRUITING NA 159 participants

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

Avantec Vascular

NCT06321575

RECRUITING 150 participants

Using SnapshotNIR With Provocative Leg Maneuver for PAD Assessment

Kent Imaging

NCT06237621

RECRUITING Phase 1 144 participants

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

Shahid Baba

NCT06480760

RECRUITING NA 120 participants

Randomized Clinical Trial for Ewing Amputation in the VA

VA Office of Research and Development

NCT05437562

RECRUITING NA 100 participants

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

LimFlow

NCT05313165

RECRUITING Phase 4 70 participants

Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

University of Nebraska

NCT02842424

RECRUITING 70 participants

Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status

University of Virginia

NCT06009276

RECRUITING Phase 2 64 participants

Passive Stretching in Peripheral Arterial Disease Patients

University of Wisconsin, La Crosse

NCT06420752

RECRUITING NA 60 participants

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

University of Nebraska

NCT06409949

RECRUITING NA 60 participants

Assessment of the Utility of the Pantheris Small Vessel (SV) System

Avinger

NCT04793581

RECRUITING 50 participants

CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

Yale University

NCT05145478

RECRUITING NA 50 participants

The ROAMM-EHR Study

University of Florida

NCT06263322

RECRUITING NA 40 participants

Fuzzy Wale Compression Stockinet to Promote Healing Following Transtibial Amputation for Peripheral Arterial Disease

Mayo Clinic

NCT06308562

RECRUITING Phase 2 34 participants

Fisetin to Reduce Senescence and Mobility Impairment in PAD

Northwestern University

NCT06399809

RECRUITING NA 30 participants

Augmentation of Limb Perfusion With Contrast Ultrasound

Oregon Health and Science University

NCT03195556

RECRUITING 25 participants

Use of Thermal Imaging Camera to Assess Perfusion Before and After Vascular Intervention

University Hospitals Cleveland Medical Center

NCT06544135

RECRUITING NA 24 participants

Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease

University of Nebraska

NCT06389149

RECRUITING Early Phase 1 20 participants

Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

University of Nebraska

NCT06319339

RECRUITING Phase 1 20 participants

Carnosine for Peripheral Arterial Disease Patients

Shahid Baba

NCT05371145

RECRUITING NA 15 participants

SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease

University of Nebraska

NCT06480786

RECRUITING NA 10 participants

Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy

Indiana University

NCT07336381

ACTIVE NOT RECRUITING 458 participants

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

Yale University

NCT04710563

ACTIVE NOT RECRUITING NA 300 participants

SELUTION4SFA Trial

M.A. Med Alliance S.A.

NCT05132361

ACTIVE NOT RECRUITING NA 188 participants

TORUS 2 IDE Clinical Study

Endologix

NCT04130737

ACTIVE NOT RECRUITING NA 177 participants

A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)

Micro Medical Solution

NCT03477604

ACTIVE NOT RECRUITING Phase 4 75 participants

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

Vanderbilt University Medical Center

NCT05009862

ACTIVE NOT RECRUITING Phase 1 40 participants

BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

BioGenCell

NCT02805023

COMPLETED 595 participants

BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients

Northwestern University

NCT02276781

COMPLETED NA 300 participants

Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon

Spectranetics Corporation

NCT01858428

COMPLETED 271 participants

Effectiveness of Medical Therapy, Endovascular Therapy, and Surgery for Peripheral Arterial Disease

Kaiser Permanente

NCT01588067

COMPLETED NA 267 participants

Evaluation of the GORE TIGRIS Vascular Stent

W.L.Gore & Associates

NCT01576055

COMPLETED NA 230 participants

The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD

University of West Florida

NCT04089943

COMPLETED NA 220 participants

Mechanisms That Produce the Leg Dysfunction of Claudication & Treatment Strategies

University of Nebraska

NCT01970332

COMPLETED 215 participants

The Impact of Diabetes on REvascularization

Vanderbilt University Medical Center

NCT03085524

COMPLETED NA 210 participants

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

Northwestern University

NCT01408901

COMPLETED Phase 2 203 participants

Edoxaban in Peripheral Arterial Disease

Daiichi Sankyo

NCT01802775

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 5
Phase 3 3
Phase 4 4

Named interventions

Most-linked intervention names on Peripheral Arterial Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Atherectomy Device
2 trials
Plain (Uncoated) Balloon Angioplasty (PTA) Device
2 trials
Jetstream Atherectomy System Device
1 trials
BOLD-MRI Other
1 trials
Bare Temporary Spur Stent System Device
1 trials
Optical Coherence Tomography Other
1 trials
Blood Pressure Measurement Procedure
1 trials

US sites by state

Facility locations filed on Peripheral Arterial Disease trials. A trial with sites in several states counts in each.

California 24 trials
Illinois 21 trials
Florida 20 trials
Texas 16 trials
Michigan 16 trials
Connecticut 14 trials
North Carolina 12 trials
Tennessee 11 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Peripheral Arterial Disease page

80 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 35 Peripheral Arterial Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • University of Nebraska sponsors the most Peripheral Arterial Disease trials on record, review their full trial history before evaluating a specific study. See University of Nebraska's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peripheral Arterial Disease condition card totals 80 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.